Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, Sysmex Ink Cancer MDx Pact

NEW YORK (GenomeWeb News) – Epigenomics and Japanese firm Sysmex today said that they have entered into a research and development collaboration aimed at developing a molecular diagnostics assay for cancer based on an Epigenomics biomarker.

The companies will evaluate the suitability of Sysmex's molecular diagnostics instrumentation for detecting DNA methylation cancer biomarkers in blood. Sysmex will use Epigenomics' mSEPT9 Methylation Detection Assay as a benchmark for development of its assay. Sysmex's plan is to develop and sell in Japan a blood test for early detection of colorectal cancer based on Epigenomics' mSEPT9 biomarker.

The firms also said that they have entered into negotiations for Sysmex to take a non-exclusive license to mSEPT9.

Sysmex will have access to Epigenomics' technologies through R&D licenses and technology transfer. It also will receive R&D support from Berlin-based Epigenomics. In return, Epigenomics will receive license fees, R&D funding, and reimbursements. It also will sell its mSEPT9 research-use only assay to Sysmex.

"With Sysmex we expect to create a route to the attractive Japanese market for our early cancer detection franchise," said Epigenomics CEO Geert Nygaard in a statement.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.